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Two daptomycin (DAP) regimens were evaluated in a pharmacokinetic/pharmacodynamic (PK/PD) model,
and the mutants recovered were examined for changes in phenotypic characteristics. Three Enterococcus
faecium strains (vancomycin-resistant Enterococcus [VRE] ATCC 51559, VRE 12311, and VRE SF 12047) were
utilized in a 7-day, 1-compartment in vitro PK/PD model. The simulated dosing regimens were DAP at 6
mg/kg/day (free Cmax [fCmax]  7.9 g/ml, half-life [t1/2]  8 h) and DAP at 10 mg/kg/day (fCmax  13.17 g/ml,
t1/2  8 h). Samples were plated daily on Mueller-Hinton agar containing DAP at 16 g/ml and 50 mg/liter
Ca2 to assess the emergence of DAP resistance. For each strain, the mutant with the highest DAP MIC was
then evaluated for changes in relative surface charge, cell wall thickness, and cytoplasmic membrane depo-
larization induced by DAP. The initial DAP MICs were 4 g/ml for all 3 strains. A dose-dependent response
and regrowth were observed for DAP 6 mg/kg/day and DAP 10 mg/kg/day against all 3 strains. Mutants of VRE
ATCC 51559 (MIC  128 and 64 g/ml) and VRE 12311 (MIC  256 and 32 g/ml) were recovered from the
DAP 6 mg and DAP 10 mg regimen, respectively. For VRE SF 12047, a mutant (MIC  64 g/ml) was recovered
from the DAP 6 mg model. All mutants displayed an increase in relative surface charge compared to those of
their respective parent strains. The DAP-resistant mutants displayed a 43 to 58% increase in cell wall thickness
(P < 0.0001), while DAP membrane depolarization decreased by 53 to 65% compared to that of the susceptible
strains. VRE with DAP resistance displayed increased surface charge, increased cell wall thickness, and
decreased depolarization induced by DAP, consistent with previous observations in Staphylococcus aureus with
reduced DAP susceptibility. Further characterization of DAP-resistant VRE is warranted.
Daptomycin is a cyclic lipopeptide antibiotic that has bacte-
ricidal activity against a wide variety of Gram-positive bacteria,
including methicillin-resistant Staphylococcus aureus and van-
comycin-resistant enterococci (VRE) (4). Although clinical
strains of S. aureus and enterococci displaying nonsusceptibility
and resistance to daptomycin have been reported, the mecha-
nism of this phenotype has not been clearly elucidated (2, 4, 16,
18, 20–22, 26, 31, 33, 34). The majority of work in this area has
concentrated on S. aureus. Mutations and/or changes in the
expression of several genes (mprF, yycG, rpoB, rpoC, and dlt-
ABCD) and alterations within the cell membrane and cell wall
(fluidity, membrane potential, membrane proteins, and the
amount and distribution of phospholipids) have been discov-
ered but are not universally found in nonsusceptible strains
(17, 22, 29, 37, 38).
Recent studies investigating S. aureus strains developing
daptomycin nonsusceptibility during daptomycin therapy have
revealed a decrease of cell membrane depolarization second-
ary to daptomycin exposure (20, 22). In addition, daptomycin
nonsusceptibility has been associated with vancomycin-inter-
mediate S. aureus (VISA) and an increase in cell wall thickness
(6, 11). The mechanism of reduced daptomycin susceptibility is
hypothesized to be secondary to an affinity trapping of antibi-
otic molecules in the thickened cell wall (11). Daptomycin-
nonsusceptible S. aureus strains have been shown to have di-
minished daptomycin and cationic peptide binding to the
cytoplasmic membrane secondary to an increase in positive cell
surface charge (20, 22, 37).
Mutations in the mprF gene have been commonly found in
postexposure clinical isolates that have developed nonsuscep-
tibility to daptomycin (37, 38). The MprF protein is responsible
for modifying net surface charge by lysinylation of the mem-
brane phosphatidylglycerol (PG) to generate lysyl-PG (LPG)
and translocation of the positively charged phospholipids to
the outer leaflet of the cytoplasmic membrane (14, 29). Re-
cently, Yang et al. have identified increased expression of mprF
and dltABCD in daptomycin-nonsusceptible strains of S. aureus
(29, 37, 38). The operon dltABCD contributes to the net pos-
itive surface charge by the D-alanylation of wall teichoic acids
(37). A shift in the cytoplasmic membrane surface charge to-
ward a more positive state is thought to impede binding via
repulsion of the daptomycin-Ca2 complex, the active form
that simulates a cationic antimicrobial peptide (20, 37).
In stark contrast, only three studies have examined genetic
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changes in enterococci resistant to daptomycin (1, 5, 30). Two
gene clusters (EF2694 to EF2701 and EF1751 to EF1753)
associated with cell membrane proteins and the phage shock
protein C were found to be upregulated in daptomycin-resis-
tant Enterococcus faecalis (5). Examination of a clinical iso-
genic pair of E. faecalis isolates found alterations in genes
associated with phospholipid metabolism and a cell envelope
stress response system (1). It has previously been demon-
strated that deletion of dltA in Enterococcus faecium leads to
increased susceptibility to cationic peptides; therefore, it seems
logical that an increase in the expression of the dltABCD
operon would lead to decreased daptomycin susceptibility (15).
E. faecalis possesses the ability to increase its cell wall thickness
as a mechanism to develop resistance to monolaurin, a fatty
acid ester with antibacterial activity via action on the mem-
brane (13). Therefore, verification of the changes in the cyto-
plasmic membrane, cell wall, and cationic peptide binding are
important to understand daptomycin resistance in enterococci.
The purpose of the current study was to evaluate two dap-
tomycin dosing regimens (6 and 10 mg/kg/day) in a 1-compart-
ment pharmacokinetic/pharmacodynamic (PK/PD) model and
examine recovered mutants for phenotypic characteristics and
mechanisms of daptomycin resistance (7, 25).
(This study was presented as a poster presentation at the
21st European Congress of Clinical Microbiology and Infec-
tious Diseases/27th International Congress of Chemotherapy
[ECCMID/ICC], Milan, Italy, 2011.)
MATERIALS AND METHODS
Bacterial strains. The following vancomycin-resistant E. faecium strains (vanA
positive) were examined: VRE SF 12047, VRE 12311, and American Type
Culture Collection (ATCC) 51559 (23).
Antimicrobials. Daptomycin and vancomycin (Sigma-Aldrich Co., St. Louis,
MO) were commercially purchased. Stock solutions were freshly prepared daily
according to Clinical and Laboratory Standards Institute (CLSI) recommenda-
tions (8).
Media. Mueller-Hinton broth II (Difco, Detroit, MI) with 25 mg/liter of
calcium and 12.5 mg/liter magnesium (MHB) was used for vancomycin suscep-
tibility testing. Due to its dependence on calcium for antimicrobial activity, MHB
II was supplemented to 50 mg/liter of calcium (50 SMHB) for susceptibility
testing and 1-compartment in vitro PK/PD models containing daptomycin. Col-
ony counts were determined using brain heart infusion agar (BHIA; Difco,
Detroit, MI) plates.
Susceptibility testing. MICs were determined in duplicate by broth microdi-
lution at 106 CFU/ml in MHB as specified above, according to CLSI guidelines
(8).
One-compartment in vitro PK/PD model. An in vitro PK/PD model consisting
of a 250-ml 1-compartment glass chamber with multiple ports for the removal of
medium, delivery of antibiotics, and collection of bacterial and antimicrobial
samples was utilized. The apparatus was prefilled with medium, and antibiotics
were administered as boluses over 1 min into the central compartment via an
injection port. All model simulations were conducted over 168 h and were
performed in duplicate to ensure reproducibility. A starting inoculum of approx-
imately 8 log10 CFU/ml was used. Each model was placed in a 37°C water bath
for the duration of the experiment, with a magnetic stir bar to produce contin-
uous mixing of the medium. Daptomycin was added to models to achieve expo-
sures reflecting approximate free (f) daptomycin concentrations based on its
protein binding (91%) (3). Regimens consisted of daptomycin at 6 mg/kg every
24 h (estimated fCmax, 7.9 g/ml; half-life [t1/2]  8 h) and daptomycin 10 mg/kg
every 24 h (estimated fCmax, 13.17 g/ml; t1/2  8 h) (3). A peristaltic pump
(Masterflex; Cole-Parmer Instrument Company, Chicago, IL) was used to con-
tinually replace antibiotic-containing medium with fresh 50 SMHB at a rate
simulating the t1/2 h of daptomycin.
Pharmacodynamic samples from each model (1 ml) were collected at 0, 4, 8,
24, 28, 32, 48, 56, 72, 96, 120, 144, and 168 h and serially diluted in cold normal
saline (0.9% NaCl). Bacterial counts were determined by plating 100-l aliquots
of each diluted sample on BHI, using an automated spiral dispenser (Whitley
automatic spiral plater; Don Whitley Scientific Limited, West Yorkshire, Eng-
land). Plated samples were incubated at 37°C for 24 h, and colony counts (log10
CFU/ml) were determined using a laser colony counter (ProtoCOL version
2.05.02; Synbiosis, Cambridge, England). The limit of detection for this method
of colony count determination is 2.0 log10 CFU/ml. For all samples, antimicrobial
carryover was accounted for by serial dilution of the plated samples. If the
anticipated dilution was near the MIC, then vacuum filtration was also used.
When vacuum filtration was used, samples were washed through a 0.45-m filter
with normal saline to remove the antimicrobial agent. Filters were then plated
onto BHI and incubated at 37°C for 24 h. The model time-kill curves were
determined by plotting mean colony counts (log10 CFU/ml) from each model
versus time. Antibacterial activity was defined by the following reductions in the
starting inoculum: bactericidal, 3 log10 (99.9% kill); bacteriostatic, 3 log10
CFU/ml; or inactivity, no reduction. The time to achieve a 99.9% bacterial load
reduction was determined by linear regression (if r2 was 0.95) or visual inspec-
tion of log10 CFU/ml.
Emergence of daptomycin resistance. Mutants with increased daptomycin
MIC values were recovered from the model in the following manner. Samples
(100 l) from the 24, 48, 72, 96, 120, 144, and 168 h time points were plated on
Mueller-Hinton agar (Difco, Detroit, MI) supplemented with 50 mg/liter Ca2
and containing daptomycin at 16 g/ml. Plates were visually inspected for growth
after 24 and 48 h of incubation at 37°C in both aerobic and anaerobic conditions.
MIC testing was performed on the overall population at 0, 96 (midpoint), and
168 h. MIC testing was performed on the mutants (if available) at the first time
point where regrowth occurred, at 96 h (midpoint), and at 168 h.
PFGE. Pulsed-field gel electrophoresis (PFGE) of SmaI DNA digests was
performed to verify relatedness of parent strains and derivative mutants selected
in the PK/PD models. Gels were run at 6 V/cm, 14°C on a 0.8% agarose gel with
pulse times of 5 to 35 s for 19 h using a CHEF-DRIII apparatus (Bio-Rad
Laboratories, Richmond, CA), as previously described (12). Strain relatedness
was determined by visual inspection of the gel using the criteria of Tenover et al.
(36).
Cytochrome c binding. The relative surface charge was determined following
a modified protocol of the method described by Kraus et al. (24). Overnight
cultures (5 ml) in brain heart infusion (BHI; Difco, MI) were centrifuged at 4,000
RPM for 10 min. The pellet was washed twice with MOPS (morpholinepropane-
sulfonic acid) buffer (20 mm, pH  7.0) and then resuspended in 1 ml of MOPS.
A volume of 0.1 ml of the bacterial suspension was serially diluted in normal
saline and spiral plated onto BHI plates in order to assess the inoculum size of
each sample. Plates were incubated at 37°C for 18 to 24 h prior to reading. A
volume of 0.1 ml of cytochrome c from bovine heart (5 mg/ml; Sigma-Aldrich
Co., St. Louis, MO) was added to the remaining 0.9 ml of the bacterial suspen-
sion in MOPS. The mixture was incubated at room temperature for 30 min, and
then cells were pelleted by centrifugation at 13,000 rpm for 5 min. The absor-
bance of the supernatant was measured at 530 nm using a spectrophotometer
(SpectraMax M5; Molecular Devices, Sunnyvale, CA), and the concentration of
cytochrome c present was quantified using a standard curve derived from the
regression line, adjusted to 109 CFU/ml.
TEM. Cell wall thickness was determined by transmission electron microscopy
(TEM) as described previously (10). Ultrathin sections were evaluated at a
magnification of 48,000 with a JEOL 100CX electron microscope, and images
were captured with a MegaView III side-mounted digital camera. The resulting
images were analyzed using ImageJ 1.39t software. Cell wall thickness was de-
termined for at least 25 cells per sample using four separate quadrants of each
cell for a total of 100 measurements per sample.
Determination of cytoplasmic membrane depolarization. The ability of dap-
tomycin to depolarize the cytoplasmic membrane was determined using a mod-
ified protocol of the method using the membrane potential-sensitive fluorescent
dye DiSC3 (35). Enterococci were grown in 50 SMHB to the early exponential
phase (optical density at 600 nm [OD600]  0.25). Cells were pelleted, washed
twice with HEPES buffer (pH 7.2, 50 mg/liter Ca2), and then resuspended in
HEPES buffer at an OD600 of 0.2. A volume of 0.04 ml of DiSC3 (0.1 mg/ml) was
added to 2 ml of the bacterial suspension in HEPES in a polystyrene fluorometer
cuvette (Fisher Scientific) containing a stir bar, and the cuvette was placed in the
heated (37°C) chamber of a Fluoromax-3 spectrofluorometer (Horiba Jobin
Yvon). The dye was allowed to load the cell for 10 min, and then 100 mM KCl
was added. Nisin and daptomycin were added 2 min later. The parameters were
622 nm (excitation) and 670 nm (emission). Measurements were collected for 60
min after addition of drugs. The drug regimens consisted of a control (HEPES),
nisin (25 g/ml), and daptomycin (8 g/ml). The membrane potential-dissipating
activity of daptomycin at 60 min was calculated using the following formula: %
membrane depolarization  100  [(Fd  Fc)/(Fn  Fc)], where Fd is the
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fluorescence measured with daptomycin, Fc is the fluorescence measured with
the buffer, and Fn is the fluorescence measured with nisin. The results presented
are the means of 2 independent experiments.
Statistical analysis. Paired continuous data were evaluated with a paired t test
or sign test (if distribution was not normal). A P value of 0.05 was considered
significant.
RESULTS
Susceptibility testing. Vancomycin and daptomycin MICs
for study isolates are displayed in Table 1.
One-compartment in vitro PK/PD model. The results of the
7-day, 1-compartment models are displayed in Table 2. Dap-
tomycin simulated regimens of 6 mg/kg/day and 10 mg/kg/day
produced dose-dependent responses in VRE SF 12047 and
VRE 12311. Daptomycin simulated regimens of 6 mg/kg/day
produced mutants with elevated daptomycin MIC values for all
strains, while 10 mg/kg/day produced mutants for VRE 12311
and VRE ATCC 51559. Regrowth occurred with both dosing
regimens in all strains.
Emergence of derivative mutants with increased daptomycin
MICs. For VRE SF 12047, only one mutant (MIC 16 to 32
g/ml) was recovered at 168 h during exposure to the dapto-
mycin simulated regimen of 6 mg/kg/day. For both VRE 12311
and VRE ATCC 51559, mutants were recovered from both
simulated regimens at the time of first regrowth and all time
points tested thereafter. The mutants recovered from the DAP
6 mg/kg/day 168 h sample were chosen as the isogenic pair to
be tested secondary to having the highest MIC values.
PFGE. Pulsed-field gel electrophoresis (PFGE) confirmed
the strain relatedness of the three strains utilized for the in
vitro PK/PD model and the respective mutants recovered from
the 168 h PD sample for the daptomycin 6 mg/kg simulation.
Cytochrome c binding. The relative cell surface charges as
determined by cytochrome c binding experiments are displayed
in Fig. 1. For the isogenic pairs, all E. faecium mutants with
elevated daptomycin MIC values had a decrease in cytochrome
c binding, suggesting an increase in cell surface positivity com-
pared to that of the daptomycin-susceptible parent strain.
TEM. The TEM results for cell wall thickness are displayed
in Table 1 and Fig. 2. For the isogenic pairs, the E. faecium
mutants with elevated daptomycin MIC values displayed sig-
nificant increases in mean cell wall thickness, increasing from
30.3 nm to 43.5 nm (43% increase), from 22.2 nm to 32.4 nm
(46% increase), and from 24.9 nm to 39.5 nm (58% increase)
for VRE SF 12047, VRE 12311, and VRE ATCC 51559, re-
spectively (P  0.0001 for all comparisons).
Determination of cytoplasmic membrane depolarization.
The effect of daptomycin on the cytoplasmic membrane in E.
faecium isolates was evaluated using the membrane potential-
TABLE 1. Susceptibility testing and transmission electron microscopy
results for Enterococcus faecium strains and their mutants
Straina
MIC (g/ml) Cell wall
thickness  SD (nm)Vancomycin Daptomycin
VRE SF 12047 	256 4 30.3  5.5
VRESF 12047 M 	256 64 43.5  9.2
VRE 12311 	256 4 22.2  4.5
VRE 12311 M 	256 256 32.4  5.2
VRE ATCC 51559 	256 2-4 24.9  2.6
VRE ATCC 51559 M 	256 128 39.5  6.2
a M, mutant recovered from pharmacodynamic sample at 168 h in model
simulating daptomycin at 6 mg/kg every 24 h.
TABLE 2. Daptomycin activity and changes in MIC values for the 1-compartment in vitro pharmacokinetic/pharmacodynamic model
Strain Daptomycin dose Maximum kill(log10 CFU/ml)
Time of 1st
regrowth (h)
Inoculum at
168 h (log10
CFU/ml)
MIC (g/ml)a
Regrowth (Mut)
96 h 168 h
Pop Mut Pop Mut
VRE SF 12047 6 mg/kg 3.73 72 8.65 NA 16 NA 16 32–64
10 mg/kg 6.96 96 4.32 NA 4 NA 4 NA
VRE ATCC 51559 6 mg/kg 3.22 24 7.86 16 16–32 64–128 16 64–128
10 mg/kg 3.27 24 7.9 32 16–32 32 16 32–64
VRE 12311 6 mg/kg 2.7 24 7.94 16–32 16–32 64 16 128–256
10 mg/kg 2.47 48 7.44 32 8 32 16 32
a Mut, recovered mutant; Pop, overall bacterial population; NA, not applicable.
FIG. 1. Binding of cationic cytochrome c by isogenic Enterococcus
faecium strains and their mutants from the 1-compartment model.
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sensitive fluorescent dye DiSC3. Dye was added into the medium
containing bacteria and allowed to penetrate and accumulate
inside the cells, and the fluorescence measured during the assay
represents the amount of dye present in the medium. If the
bacterial membrane is depolarized in the presence of drug, dye
will escape from inside the cells out to the medium, causing an
increase in measurable fluorescence.
All daptomycin-resistant mutants demonstrated a decrease
in depolarization due to daptomycin compared to that of the
daptomycin-susceptible parent strains (Fig. 3). For VRE 12311
and the VRE 12311 mutant, daptomycin-induced depolariza-
tion decreased significantly, from 93.03%  9.86% (mean 
standard deviation) to 27.65%  4.95% (P  0.017). VRE
ATCC 51559 and its mutant showed a similar decrease
(75.95%  2.64% versus 22.29%  11.45%, P  0.06). The
daptomycin depolarization was 98.52%  5.29% for VRE SF
12047 and 45.89%  4.42% for the VRE SF 12047 mutant
(P  0.008), illustrating a 	50% loss in daptomycin’s depolar-
ization ability for this VRE strain.
DISCUSSION
To our knowledge, this is the first published paper to discuss
phenotypic changes and potential mechanisms associated with
daptomycin-resistant E. faecium strains, the predominant spe-
cies responsible for nosocomial infections caused by VRE. It is
also the first study to utilize multiple isogenic pairs developed
in vitro. The three strains utilized in the in vitro PK/PD models,
VRE SF 12047, VRE 12311, and VRE ATCC 51559, varied in
their susceptibility to daptomycin activity and in their propen-
sity to develop daptomycin-resistant mutants during therapy,
therefore allowing the recovery of mutants with MICs ranging
from 32 to 256 g/ml. Our study examined the activity of
daptomycin and the development of resistance in a high-inoc-
FIG. 2. Cell wall thickness for single cell of VRE ATCC 51559 (A) and VRE ATCC 51559 M (B).
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ulum and high-MIC setting. Daptomycin displayed the most
potent and sustained activity against VRE SF 12047. The pro-
pensity of this strain to develop resistance (only one mutant
recovered at 168 h under daptomycin pressure of 6 mg/kg/day)
was strikingly less than that of the other two strains tested.
VRE ATCC 51559 and VRE 12311 developed resistance to
daptomycin at 24/24 h and 24/48 h under exposure to dapto-
mycin at 6 and 10 mg/kg/day, respectively. The variability
among strains highlights the need for further research to de-
termine the optimal daptomycin dose for enterococcal infec-
tions and to prevent the emergence of resistance.
Comparison of the isogenic in vitro-derived pairs found a
small increase in cell surface positivity (decrease in cytochrome
c binding) in the daptomycin-resistant mutants. An increase in
the positive cell surface charge of E. faecium strains relative to
that of the daptomycin-susceptible parent strains may be asso-
FIG. 3. Cytoplasmic membrane depolarization of VRE ATCC 51559 (A) and the VRE ATCC 51559 mutant (B), VRE 12311 (C) and the VRE
12311 mutant (D), and VRE SF 12047 (E) and the VRE SF 12047 mutant (F). Black lines show results with nisin, dark-gray lines show results
with daptomycin, and light-gray lines show results for control.
4752 STEED ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on A
pril 29, 2015 by U
niversity of K
ansas
http://aac.asm
.org/
D
ow
nloaded from
 
ciated with daptomycin resistance. Preliminary data from one
study examining a clinical E. faecalis isogenic pair also found a
decrease in cytochrome c binding in the daptomycin-resistant
strain (MIC  16 g/ml) compared to that of the daptomycin-
susceptible (MIC  1 g/ml) parent (27). As stated previously,
daptomycin is bound to calcium in its active state, forming a
positively charged complex that simulates a cationic peptide
antibiotic. It is hypothesized that, in S. aureus, a change in the
cytoplasmic membrane surface charge from negative to more
positive contributes to the increase in daptomycin MIC values
by charge repulsion of the positively charged daptomycin-Ca2
complex (20, 37). This increase in membrane surface charge in
S. aureus with increased daptomycin MIC values has been
demonstrated in clinical, in vitro, and genetically manipulated
isolates via decreased binding of cytochrome c or other cat-
ionic peptide antibiotics (14, 20, 24, 29, 37). It would appear
that enterococci also possess the ability to alter cytoplasmic
membrane surface charge and this contributes to daptomycin
resistance. Further analysis, including the use of more sensitive
assays, is required to confirm these findings in clinical E. fae-
cium strains and explore the mechanisms by which enterococci
are able to alter cytoplasmic membrane surface charge.
With regard to cell wall thickness, comparison of the in
vitro-derived isogenic pairs revealed a significant increase for
all the daptomycin-resistant E. faecium mutants compared to
the cell wall thickness of the parent strain. This finding suggests
that thickening of the cell wall is one mechanism by which E.
faecium may increase its resistance to daptomycin under pro-
longed exposure. Previous studies have shown that enterococci
possess the ability to thicken cell walls in an effort to survive
under selective pressure. Comparison of E. faecalis AR01/
DGVS and DGRM2, a monolaurin-resistant mutant, found an
increase in cell wall thickness and contraction of the cytoplasm in
DGRM2 compared to these characteristics in AR01/DGVS
in the presence of monolaurin (13). Preliminary work examin-
ing the same clinical E. faecalis isogenic pair (daptomycin MIC
values of 1 and 16 g/ml) mentioned previously found both an
increase in cell wall thickness and localized protrusions in the
cell envelope in the mutant strain (28). Increases in daptomy-
cin MIC values in S. aureus have been associated with increases
in cell wall thickness and VISA strains (6, 11, 29). In S. aureus,
thickening of the cell wall is hypothesized to contribute to
decreased susceptibility to daptomycin via an affinity trapping
mechanism within the cell wall (11). Based on the data for the
in vitro-derived isogenic pairs, it would appear that a thickened
cell wall in E. faecium contributes to daptomycin resistance.
Daptomycin acts like a cationic antimicrobial peptide in its
active calcium-bound form and exerts bactericidal activity in S.
aureus through the insertion of a lipophilic acyl tail into the
cytoplasmic membrane, leading to potassium efflux, destruc-
tion of the ion concentration gradient, membrane depolariza-
tion, and probably, more generalized disruption of the cell
membrane (9, 19). While the mechanism of action of dapto-
mycin has not been specifically studied in Enterococcus spp., it
is logical that it would act via similar mechanisms in these two
Gram-positive organisms. Clinical S. aureus strains with de-
creased susceptibility to daptomycin have been found to have
decreases in membrane depolarization from daptomycin com-
pared with their respective isogenic susceptible strains (20, 22).
The in vitro-derived E. faecium mutants in this study displayed
similar characteristics, with decreased depolarization due to
daptomycin compared to that in their susceptible isogenic par-
ent strains. In addition, preliminary data examining the clinical
E. faecalis isogenic pair also found decreased membrane de-
polarization by daptomycin in the resistant strain (MIC  16
g/ml) compared to that in the susceptible parent (MIC  1
g/ml) (27).
This is the first study to examine phenotypic characteristics
associated with daptomycin-resistant E. faecium strains and is
strengthened by the number of in vitro-derived strains exam-
ined. Even with its novelty, positive findings, and larger num-
ber of strains, this study does have limitations. Since this study
utilized an in vitro model to simulate clinical daptomycin ex-
posure, it is logical that the mechanisms by which the examined
E. faecium strains developed resistance to daptomycin will
more closely mimic in vivo conditions than other laboratory
methods, such as serial passage. It is still possible, however,
that daptomycin-resistant E. faecium strains developed in vivo
may differ from the in vitro-developed strains here, because E.
faecium isolates in the human body are also exposed to cationic
peptides that are part of the immune system. The lack of white
cells in the model compared to the immune system may also
alter the rate of resistance selection in vitro compared to the
rate in vivo. We also did not examine any genetic changes
associated with the emergence of daptomycin-resistant strains.
Clearly, more research is needed to continue to explore the
mechanisms by which E. faecium strains change their cell wall
and cytoplasmic membrane, leading to the development of
daptomycin resistance. In S. aureus, changes in surface charge
are secondary to alterations in phospholipid asymmetry (trans-
location of the positively charged phospholipids to the outer
leaflet of the cytoplasmic membrane) and increased alanyla-
tion of cell wall teichoic acid (14, 20, 29, 37). Research into the
phosphatidylglycerol content of the cytoplasmic membrane of
various species of bacteria has found differences in amino acid
substrate specificity (32). Enterococcus faecium TX1330 pos-
sesses a multispecific amino acid aminoacylphosphatidylglyc-
erol synthase, allowing it to synthesize greater amounts of
phosphatidylglycerols and perform elaborate remodeling of
these lipids within the cell membrane in response to environ-
mental stress (32). Therefore, while changes in phospholipids
may also be responsible for the daptomycin resistance in en-
terococci, the exact mechanisms may vary between the species.
Additional work examining the mechanisms, including the
dose exposure, leading to the development of daptomycin re-
sistance in enterococci is needed.
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